From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts
Clinical response | Number of patients (%) |
---|---|
Confirmed ORR (CR + PR) | 20 (53%) |
Complete response (CR) | 13 (34%) |
DCR (CR + PR + SD**) | 28 (74%) |
ORR in PD-L1 negative (n = 14) | 6 (43%) |
ORR, PD-L1 positive (n = 21) | 13 (62%) |
ORR, PD-L1 unknown (n = 3) | 1 (33%) |
ORR, LDH > ULN (n = 11) | 5 (45%) |
ORR, liver metastases (n = 10) | 5 (50%) |